38,167 results match your criteria Lymphoma Lymphoblastic


Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.

Swiss Med Wkly 2022 Jun 20;152:w30186. Epub 2022 Jun 20.

Department of Medical Oncology and Haematology, University Hospital Zurich, Switzerland.

Aim Of The Study: Chimeric antigen receptor T (CAR-T) cells are a powerful form of immune-cell therapy for patients with relapsed/refractory B-cell lymphoma and acute B lymphoblastic leukaemia. CAR-T cells have been commercially available in Switzerland since 2018. Because of the complexity and costs of this treatment it is critical to review patient outcomes in real-world settings, to examine whether the promising results from pivotal trials can be reproduced and to identify clinical parameters that determine their efficacy. Read More

View Article and Full-Text PDF

Ectopic expression of a combination of 5 genes detects high risk forms of T-cell acute lymphoblastic leukemia.

BMC Genomics 2022 Jun 24;23(1):467. Epub 2022 Jun 24.

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Background: T cell acute lymphoblastic leukemia (T-ALL) defines a group of hematological malignancies with heterogeneous aggressiveness and highly variable outcome, making therapeutic decisions a challenging task. We tried to discover new predictive model for T-ALL before treatment by using a specific pipeline designed to discover aberrantly active gene.

Results: The expression of 18 genes was significantly associated with shorter survival, including ACTRT2, GOT1L1, SPATA45, TOPAZ1 and ZPBP (5-GEC), which were used as a basis to design a prognostic classifier for T-ALL patients. Read More

View Article and Full-Text PDF

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.

Blood Cancer J 2022 Jun 24;12(6):96. Epub 2022 Jun 24.

Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing, P. R. China.

Chimeric antigen receptor-engineered T (CAR-T) cells have shown promising efficacy in patients with relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL). However, challenges remain including long manufacturing processes that need to be overcome. We presented the CD19-targeting CAR-T cell product GC007F manufactured next-day (FasTCAR-T cells) and administered to patients with R/R B-ALL. Read More

View Article and Full-Text PDF

Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.

Leuk Lymphoma 2022 Jun 24:1-11. Epub 2022 Jun 24.

Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, P.R. China.

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype of ALL. We retrospectively studied 70 cases with Ph-like ALL and here present the largest study of CAR-T cell treatment and haplo-HSCT for this leukemia. Median age was 26 years and median leukocyte count was 31. Read More

View Article and Full-Text PDF

Flow Cytometric Detection of Malignant Blasts in Cerebrospinal Fluid: A Biomarker of Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia.

Biomolecules 2022 Jun 9;12(6). Epub 2022 Jun 9.

Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.

Despite the excellent prognosis for children and adolescents with acute lymphoblastic lymphoma (ALL), the involvement of the central nervous system (CNS) represents a major therapeutic challenge. Patients who develop CNS relapse have a very poor prognosis, and since current methods cannot reliably identify patients with CNS involvement or patients at high risk of CNS relapse, all children with ALL receive CNS-directed treatment. The current golden standard for detecting CNS involvement is the assessment of cytomorphology on cytospin slides of cerebrospinal fluid (CSF). Read More

View Article and Full-Text PDF

Dysregulation of Small Nucleolar RNAs in B-Cell Malignancies.

Biomedicines 2022 May 24;10(6). Epub 2022 May 24.

Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

Small nucleolar RNAs (snoRNAs) are responsible for post-transcriptional modification of ribosomal RNAs, transfer RNAs and small nuclear RNAs, and thereby have important regulatory functions in mRNA splicing and protein translation. Several studies have shown that snoRNAs are dysregulated in human cancer and may play a role in cancer initiation and progression. In this review, we focus on the role of snoRNAs in normal and malignant B-cell development. Read More

View Article and Full-Text PDF

Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia.

Sci Rep 2022 Jun 23;12(1):10670. Epub 2022 Jun 23.

Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Despite recent progress in acute lymphoblastic leukemia (ALL) therapies, a significant subset of adult and pediatric ALL patients has a dismal prognosis. Better understanding of leukemogenesis and recognition of germline genetic changes may provide new tools for treating patients. Given that hematopoietic stem cell transplantation, often from a family member, is a major form of treatment in ALL, acknowledging the possibility of hereditary predisposition is of special importance. Read More

View Article and Full-Text PDF

Contribution of Cyclin-dependent Kinase Inhibitor 1B Genotypes to Childhood Leukemia Risk.

In Vivo 2022 Jul-Aug;36(4):1637-1642

Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.;

Background/aim: Although genetic differences in cell-cycle control genes have been associated with cancer risk, to our knowledge, no report has specifically examined the role of gene variants in childhood acute lymphoblastic leukemia (ALL). Cyclin-dependent kinase inhibitor 1B (CDKN1B; also known as p27/KIP1) is a cell-cycle regulating gene. This study aimed at investigating the association between CDKN1B genotypes and childhood ALL risk. Read More

View Article and Full-Text PDF

Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia.

Leuk Lymphoma 2022 Jun 23:1-3. Epub 2022 Jun 23.

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

View Article and Full-Text PDF

The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China.

Front Oncol 2022 6;12:846573. Epub 2022 Jun 6.

Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou, China.

Early T-cell precursor (ETP) lymphoblastic leukemia/lymphoma is a high-risk T lymphoblastic leukemia/lymphoma (T-ALL/LBL) subgroup. We performed a real-world multicenter study to explore the clinical characteristics and prognosis of adolescent and young adults (AYA) and older adult ETP leukemia/lymphoma. A total of 103 patients with ETP-ALL/LBL in five centers in China between January 2016 and February 2021 were included in this study. Read More

View Article and Full-Text PDF

[Malignant hypercalcaemia revealing acute lymphoblastic leukemia: case report].

Pan Afr Med J 2022 29;41:257. Epub 2022 Mar 29.

Service d'Hématologie Clinique, Centre Hospitalier Universitaire Mohammed VI Marrakech, Faculté de Médecine et de Pharmacie, Université Cadi Ayyad, Marrakech, Maroc.

Malignant hypercalcaemia is a metabolic emergency. Its association with solid tumors is common, whereas it has been rarely described in patients with malignant hemopathies other than multiple myeloma and T-cell leukemias/T-cell lymphomas associated with lymphotropic virus type I (HTLV-I). We here report the case of a female patient with acute lymphoblastic leukemia revealed by malignant hypercalcaemia and pathological fracture of the humerus. Read More

View Article and Full-Text PDF

Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment.

Front Immunol 2022 6;13:915590. Epub 2022 Jun 6.

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences, Beijing, China.

Measurable residual disease (MRD) positivity before haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an independent prognostic factor in determining outcomes in patients with B-cell acute lymphoblastic leukemia (ALL). In this study, we conducted a parallel comparison of the efficacy and safety in patients with suboptimal MRD response after reinduction who underwent haplo-HSCT after chimeric antigen receptor T-cell (CAR-T) therapy or chemotherapy. Forty B-cell ALL patients who relapsed after first-line chemotherapy and with an MRD ≥0. Read More

View Article and Full-Text PDF

Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma.

BMJ Case Rep 2022 Jun 22;15(6). Epub 2022 Jun 22.

Hematology and Oncology, VA West Los Angeles Medical Center, Los Angeles, California, USA.

Although patients with multiple myeloma (MM) have improved survival with current therapies, there remains a long-term risk of treatment-associated second primary malignancies. We present a case of a patient with IgG kappa MM undergoing treatment for relapsed disease who was noted to have progressive pancytopenia. For his MM, he had previously undergone autologous stem cell transplant with high-dose melphalan and had received immunomodulatory (IMiD) agents in induction, maintenance and relapse regimens. Read More

View Article and Full-Text PDF

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

N Engl J Med 2022 06;386(25):2399-2411

From Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome.

View Article and Full-Text PDF

Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission.

Chin Med J (Engl) 2022 Apr 20;135(8):940-949. Epub 2022 Apr 20.

Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing 100044, China.

Background: The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with high-risk (HR) T-cell acute lymphoblastic leukemia (T-ALL) in first complete remission (CR1) is still under evaluation. Moreover, relapse is the main factor affecting survival. This study aimed to explore the effect of allo-HSCT (especially haploidentical HSCT [haplo-HSCT]) on improving survival and reducing relapse for HR childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in order to identify who could benefit from HSCT. Read More

View Article and Full-Text PDF

The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.

Leuk Lymphoma 2022 Jun 21:1-3. Epub 2022 Jun 21.

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.

View Article and Full-Text PDF

Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.

Cytotherapy 2022 Jun 16. Epub 2022 Jun 16.

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

Chimeric antigen receptor (CAR) T-cell therapy is an individualized immunotherapy that genetically reprograms a patient's T cells to target and eliminate cancer cells. Tisagenlecleucel is a US Food and Drug Administration-approved CD19-directed CAR T-cell therapy for patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia and r/r diffuse large B-cell lymphoma. Manufacturing CAR T cells is an intricate process that begins with leukapheresis to obtain T cells from the patient's peripheral blood. Read More

View Article and Full-Text PDF

Precursor T-Lymphoblastic Lymphoma Presenting With a Cough: A Case Report.

Cureus 2022 May 15;14(5):e25011. Epub 2022 May 15.

Department of Pathology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, IND.

Lymphoblastic lymphoma (LBL) is a rare subtype of non-Hodgkin lymphoma (NHL) and the majority (85-90%) of the cases are comprised of precursor T-lymphoblastic lymphoma (T-LBL). We report a case of a 17-year-old male who presented with a productive cough for one month along with complaints of difficulty in breathing (unrelated to exertion) for four days and chest pain (left-sided, non-radiating) for two days. On clinical examination, lymphadenopathy was observed; mid jugular cervical lymph nodes were palpable on the left side, which were non-tender, matted, and approximately 1 x 1 cm in diameter. Read More

View Article and Full-Text PDF

Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia.

Cell Death Dis 2022 Jun 17;13(6):551. Epub 2022 Jun 17.

Department of Medicine and Surgery, University of Parma, Parma, 43126, Italy.

Genomic studies have identified recurrent somatic alterations in genes involved in DNA methylation and post-translational histone modifications in acute lymphoblastic leukemia (ALL), suggesting new opportunities for therapeutic interventions. In this study, we identified G9a/EHMT2 as a potential target in T-ALL through the intersection of epigenome-centered shRNA and chemical screens. We subsequently validated G9a with low-throughput CRISPR-Cas9-based studies targeting the catalytic G9a SET-domain and the testing of G9a chemical inhibitors in vitro, 3D, and in vivo T-ALL models. Read More

View Article and Full-Text PDF

Association between maternal breastfeeding and risk of systemic neoplasms of offspring.

Ital J Pediatr 2022 Jun 16;48(1):98. Epub 2022 Jun 16.

Center for Reproductive Medicine, Taihe Hospital, Hubei University of Medicine, No.32, South Renmin Road, Shiyan, 442000, China.

Background: Breastfeeding might prevent childhood cancer by stimulating the immune system.

Methods: The following databases, including PubMed, Embase, and Cochrane Library, were searched from inception to January 10, 2021.

Results: In dose-dependent manner, there was a statistically significant inverse association between any breastfeeding and the incidence of childhood cancer. Read More

View Article and Full-Text PDF

Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia.

J Immunother Cancer 2022 Jun;10(6)

Aflac Cancer and Blood Disprders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, U.S.A

Background: Black and Hispanic children with B-acute lymphoblastic leukemia (B-ALL) experience worse outcomes compared with their non-Hispanic white (NHW) counterparts. Immune-based approaches have begun to transform the therapeutic landscape in children with B-ALL. Recent studies identified several alterations in both innate and adaptive immune cells in children with B-ALL that may impact disease risk and outcome. Read More

View Article and Full-Text PDF

Mucormycosis in Children With Hematologic Malignancies: A Case Series and Review of the Literature.

Pediatr Infect Dis J 2022 Jun 13. Epub 2022 Jun 13.

From the Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht.

Background: Mucormycosis is classified as the third leading cause of invasive fungal disease in immunocompromised patients and is characterized by high morbidity and mortality (33%-56%). The aim of this study is to describe presentation, treatment and outcome of Dutch pediatric hemato-oncology patients recently diagnosed with mucormycosis and to review the literature to gain more insight specifically into contemporary outcome data.

Methods: Ten cases were diagnosed in the Princess Máxima Center for Pediatric Oncology from 2018 to 2021 and were retrospectively reviewed. Read More

View Article and Full-Text PDF

Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.

Leuk Lymphoma 2022 Jun 14:1-8. Epub 2022 Jun 14.

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.

PEG-asparaginase is a key component in treatment regimens for acute lymphoblastic leukemia (ALL). Major side effects include thrombosis and bleeding; however, there is currently no consensus on methods to prevent these complications. In this multi-center retrospective cohort study of 101 adults, we compared two prophylaxis strategies: cryoprecipitate and fresh frozen plasma (Cryo/FFP) versus cryoprecipitate and antithrombin (ATIII). Read More

View Article and Full-Text PDF

The incidence and mortality of childhood acute lymphoblastic leukemia in Indonesia: A systematic review and meta-analysis.

PLoS One 2022 13;17(6):e0269706. Epub 2022 Jun 13.

Department of Pediatrics, Universitas Padjadjaran, Bandung, Indonesia.

Background: The incidence of childhood ALL in Indonesia is still largely unknown. The widely mentioned statistics from other countries turn out to be only estimated figures. Other data do not specify the types of leukemia and are not specifically focused on children. Read More

View Article and Full-Text PDF

St. Jude Total Therapy studies from I to XVII for childhood acute lymphoblastic leukemia: a brief review.

J Egypt Natl Canc Inst 2022 Jun 13;34(1):25. Epub 2022 Jun 13.

Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 Święcickiego Street, 60-781, Poznań, Poland.

The therapy design of childhood acute lymphoblastic leukemia (ALL) has evolved over the past 60 years. The St. Jude Children's Research Hospital has developed 17 treatment protocols from 1962 to 2017, aiming to have the most effective and least toxic treatment form. Read More

View Article and Full-Text PDF

miR-146a, miR-196a2, miR-499, and miR-149 linked with susceptibility to acute lymphoblastic leukemia: A case-control study in Tunisia.

Gene 2022 Aug 9;834:146648. Epub 2022 Jun 9.

Nazarbayev University School of Medicine, Nur-Sultan (Astana), Kazakhstan. Electronic address:

Background: MicroRNAs (miRNAs) are promising biomarkers of hematological malignancies, including acute lymphoblastic leukaemia (ALL). Recent studies revealed that miRNA single nucleotide polymorphisms (miR-SNP) modulate cancer risk by regulating various signaling pathways. However, their association with altered risk of ALL yielded inconsistent results. Read More

View Article and Full-Text PDF

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2022 May 5. Epub 2022 May 5.

Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.

Introduction: Response kinetics is a well-established prognostic marker in acute lymphoblastic leukemia. The situation is not clear in multiple myeloma (MM) despite having a biomarker for response monitoring (monoclonal component [MC]).

Materials And Methods: We developed a mathematical model to assess the prognostic value of serum MC response kinetics during 6 induction cycles, in 373 NDMM transplanted patients treated in the GEM2012Menos65 clinical trial. Read More

View Article and Full-Text PDF

The prognostic effect on childhood acute lymphoblastic leukemia of CD34CD38 expressed in leukemia cells.

Hematology 2022 Dec;27(1):706-713

Department of Pediatrics, Huai'an First Hospital Affiliated to Nanjing Medical University, Jiangsu, People's Republic of China.

Objective: Acute lymphoblastic leukemia is the most common malignant disease in children. CD34 and CD38 are expressed in both normal and leukemia cells, but studies of their prognostic associations in childhood acute lymphoblastic leukemia are limited. The aim of this study was to investigate the prognostic effect of CD34 CD38 leukemia cells in this childhood cancer. Read More

View Article and Full-Text PDF
December 2022

Genomic landscape of T-cell lymphoblastic lymphoma.

Chin J Cancer Res 2022 Apr;34(2):83-94

Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Objective: T-cell lymphoblastic lymphoma (T-LBL) is an aggressive neoplasm of precursor T cells, however, detailed genome-wide sequencing of large T-LBL cohorts has not been performed due to its rarity. The purpose of this study was to identify putative driver genes in T-LBL.

Methods: To gain insight into the genetic mechanisms of T-LBL development, we performed whole-exome sequencing on 41 paired tumor-normal DNA samples from patients with T-LBL. Read More

View Article and Full-Text PDF